½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)
Myocardial Infarction (MI) Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå : 1572924
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 189 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,088,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,352,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,055,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Persistence Market Research´Â ÃÖ±Ù ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ¼¼°è ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå µ¿ÀÎ, µ¿Çâ, ±âȸ, ÃËÁø¿äÀÎ, µµÀü °úÁ¦ µî ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡ÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â 2024³âºÎÅÍ 2031³â±îÁö ¼¼°è ½É±Ù°æ»ö Ä¡·áÁ¦ ½ÃÀå ¿¹Ãø ¼ºÀå ±ËÀûÀ» °³°ýÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

½É±Ù°æ»ö Ä¡·áÁ¦ ½ÃÀå-Á¶»ç ¹üÀ§

½É±Ù°æ»öÀº ÀϹÝÀûÀ¸·Î ½ÉÀ帶ºñ·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ½É±Ù°æ»ö Ä¡·áÁ¦´Â ±Þ¼º ½É±Ù°æ»öÀ» °ü¸®Çϰí ÇâÈÄ ½ÉÇ÷°ü ÁúȯÀ» ¿¹¹æÇϱâ À§ÇÑ ¾à¼öó¸®, ¼ö¼úÀû ÁßÀç, »ýȰ½À°ü °³¼± µî ´Ù¾çÇÑ Ä¡·á¹ýÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº º´¿ø, ¿Ü·¡Áø·á¼Ò, ÀçȰ¼¾ÅÍ µî¿¡ ¼­ºñ½º¸¦ Á¦°øÇϸç Ç×Ç÷¼ÒÆÇÁ¦, º£Å¸Â÷´ÜÁ¦, ACE ¾ïÁ¦Á¦, ½ºÅ¸Æ¾, PCSK9 ¾ïÁ¦Á¦¿Í °°Àº »õ·Î¿î Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ä¡·áÁ¦¸¦ Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, Ä¡·á ¿É¼ÇÀÇ ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡ µîÀÔ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:

¼¼°è ½É±Ù°æ»öÁõ Ä¡·áÁ¦ ½ÃÀåÀº »ýȰ½À°üÀÇ º¯È­, Àα¸ °í·ÉÈ­, °íÇ÷¾Ð, ´ç´¢º´, ºñ¸¸°ú °°Àº À§Çè¿äÀÎÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ ½ÉÇ÷°ü Áúȯ ¹ßº´·ü Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Á¦Á¦ ¹× Ä¡·á Àü·«ÀÇ °³¹ß·Î Ä¡·á È¿°ú¿Í ȯÀÚ ¿¹Èİ¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. Á¶±â °³ÀÔ°ú ¿¹¹æ Á¶Ä¡ÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ½ÉÀå Ä¡·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óµµ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí, ½É±Ù°æ»öÁõ Ä¡·áÁ¦ ½ÃÀåÀº ³ôÀº Ä¡·á ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, Áö¼ÓÀûÀΠȯÀÚ ¸ð´ÏÅ͸µÀÇ Çʿ伺°ú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ Ä¡·áÁ¦¿Í ÷´Ü ¼ö¼ú¿¡ µû¸¥ ³ôÀº ºñ¿ëÀº ƯÈ÷ ½ÅÈï °æÁ¦±¹¿¡¼­ ƯÁ¤ ȯÀÚ Áý´ÜÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú ±ä ½Å¾à ½ÂÀÎ ÀýÂ÷´Â »õ·Î¿î Ä¡·áÁ¦ ½ÃÀå ÁøÀÔÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àç¹ß ¹æÁö¸¦ À§Çؼ­´Â »ýȰ½À°ü °³¼±ÀÌ Áß¿äÇϱ⠶§¹®¿¡ ȯÀÚ°¡ ó¹æµÈ Ä¡·á ¿ä¹ýÀ» Àß µû¸£´Â °Íµµ Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù.

½ÃÀå ±âȸ :

½É±Ù°æ»öÁõ Ä¡·áÁ¦ ½ÃÀåÀº ±â¼ú Çõ½Å, Àα¸ º¯È­, ÁøÈ­ÇÏ´Â ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á Ç÷§Æû ¹× ¿ø°Ý ¸ð´ÏÅ͸µ Àåºñ¿Í °°Àº µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚÀÇ MI °ü¸® ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí Ä¡·á ¿É¼ÇÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇÏ°í ½ÃÀå ¹ßÀüÀ» ÃËÁøÇϱâ À§Çؼ­´Â Á¦¾à»ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× ¿¬±¸ ±â°ü °£ÀÇ Àü·«Àû Á¦ÈÞ°¡ ÇʼöÀûÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ºÎ°¡°¡Ä¡ ÅëÂû

Á¦4Àå ¼¼°èÀÇ ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦5Àå ¼¼°èÀÇ ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : Áö¿ªº°

Á¦6Àå ºÏ¹Ì ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦7Àå À¯·´ ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦8Àå µ¿¾Æ½Ã¾Æ ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦10Àå ºÏ¹Ì ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has recently released a comprehensive report on the worldwide market for myocardial infarction (MI) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global MI therapeutics market from 2024 to 2031.

Key Insights:

MI Therapeutics Market - Report Scope:

Myocardial infarction, commonly known as a heart attack, is a leading cause of morbidity and mortality worldwide. MI therapeutics include a range of treatment modalities such as medications, surgical interventions, and lifestyle modifications aimed at managing acute myocardial infarction and preventing future cardiovascular events. The market serves hospitals, outpatient clinics, and rehabilitation centers, providing a variety of therapeutics, including antiplatelet agents, beta-blockers, ACE inhibitors, statins, and novel therapies like PCSK9 inhibitors. Market growth is driven by the increasing prevalence of cardiovascular diseases, advancements in therapeutic options, and rising healthcare expenditures.

Market Growth Drivers:

The global MI therapeutics market is propelled by several key factors, including the rising incidence of cardiovascular diseases due to lifestyle changes, aging populations, and the increasing prevalence of risk factors such as hypertension, diabetes, and obesity. Furthermore, the development of novel drug formulations and treatment strategies enhances therapeutic efficacy and patient outcomes. Growing awareness about the importance of early intervention and preventive measures also contributes to market expansion. Additionally, the expansion of healthcare infrastructure and improved access to cardiac care services play a crucial role in supporting market growth.

Market Restraints:

Despite promising growth prospects, the MI therapeutics market faces challenges related to high treatment costs, stringent regulatory approvals, and the need for continuous patient monitoring. The high costs associated with innovative therapeutics and advanced surgical procedures may limit access for certain patient populations, particularly in developing economies. Moreover, regulatory hurdles and the lengthy approval processes for new drugs can impede market entry for novel therapeutics. Ensuring patient adherence to prescribed treatment regimens also remains a challenge, as lifestyle modifications are crucial for preventing recurrent events.

Market Opportunities:

The MI therapeutics market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as telehealth platforms and remote monitoring devices, enhances patient access to MI management services and improves adherence to treatment. Additionally, the growing focus on personalized medicine and tailored therapeutic approaches can stimulate innovation and expand treatment options. Strategic partnerships between pharmaceutical companies, healthcare providers, and research institutions are essential to capitalize on emerging opportunities and drive market advancements.

Key Questions Answered in the Report:

Competitive Intelligence and Business Strategy:

Leading players in the global MI therapeutics market, including Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced therapeutics, including novel antiplatelet agents, beta-blockers, and emerging therapies for heart failure management. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, an emphasis on clinical research, evidence-based practice, and patient education enhances market growth and improves patient outcomes in the rapidly evolving MI therapeutics landscape.

Key Companies Profiled:

Myocardial Infarction (MI) Therapeutics Market Segmentation

By Drug Type

By Route of Administration

By Distribution Channel

By Region

Table of Contents

1. Executive Summary

2. Market Overview

3. Value Added Insights

4. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

5. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Region

6. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

7. Europe Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

8. East Asia Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

9. South Asia and Oceania Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

10. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

11. Middle East & Africa Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

12. Competition Landscape

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â